Education
About Us
Working with TipRanks
Follow Us
Pfizer (DE:PFE)
XETRA:PFE
PFE Stock Chart & Stats
€22.76
€0.04(0.13%)
At close: 4:00 PM EST
€22.76
€0.04(0.13%)
Day’s Range― - ―
52-Week Range€18.57 - €25.74
Previous CloseN/A
Volume2.00K
Average Volume (3M)58.13K
Market Cap
€129.17B
Enterprise Value€150.61B
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)18.8
Beta0.51
Next Earnings
May 05, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend Yield6.66%
Share Statistics
EPS (TTM)0.56
Shares Outstanding5,685,707,500
10 Day Avg. Volume76,650
30 Day Avg. Volume58,135
Financial Highlights & Ratios
PEG Ratio-4.31
Price to Book (P/B)1.52
Price to Sales (P/S)2.26
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€24.45Price Target Upside7.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Revenue StrengthRobust sales across vaccines and oncology products, including strong performance of the COVID vaccine and Prevnar, contributed to better-than-expected revenue and reinforced commercial momentum.
Obesity Program Clinical ProgressClinical trial data for the long-acting GLP-1 showed meaningful weight loss with an acceptable tolerability profile, supporting advancement to pivotal studies and strengthening the obesity drug pipeline.
Strategic Acquisitions And ReinvestmentAcquisition of Metsera, related licensing arrangements, and redeployment of asset sale proceeds into business development expand the pipeline into obesity and increase capacity for future growth initiatives.
Bears Say
GLP-1 Competitive Pricing PressurePrice cuts across the GLP-1 market and questions about the commercial attractiveness of monthly dosing could constrain pricing power and weigh on valuation for obesity entrants.
Obesity Trial Data UncertaintyOutstanding questions about tolerability, placebo effects, and patient discontinuation in obesity trial data create uncertainty about the new drug's real-world competitiveness and commercial appeal.
Revenue Erosion From Exclusivity LossLoss of exclusivity for key products combined with variable demand for infection-related treatments raises the risk of revenue erosion and may limit upside until clear new product catalysts emerge.
Pfizer News
PFE FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest stock price was €18.57 and its highest was €25.74 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is €129.17B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is May 05, 2026 which is in 88 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Feb 03, 2026. The company reported €0.56 earnings per share for the quarter, beating the consensus estimate of €0.481 by €0.079.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer pays a Quarterly dividend of €0.372 which represents an annual dividend yield of 6.66%. See more information on Pfizer dividends here
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.62.
How many shares outstanding does Pfizer have?
Pfizer has 5,685,707,500 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of €0.56 in its last earnings report, beating expectations of €0.481. Following the earnings report the stock price went down -1.916%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in DE:PFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pfizer Stock Smart Score
Company Description
Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFE Company Deck
PFE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong positives — better‑than‑expected adjusted EPS, margin expansion, meaningful cost‑savings realization, promising obesity (PF‑3944) clinical readouts with differentiated monthly dosing, robust activity on pivotal studies and approvals, and strategic acquisitions that are already contributing revenue growth. Offsetting these strengths are near‑term challenges: modest overall revenue decline (driven largely by a pronounced COVID revenue drop), a sizable $4.4 billion impairment reflecting portfolio reprioritization, upcoming LOE pressure (including ~ $1.5 billion revenue compression projected in 2026), and some GAAP volatility in the quarter. On balance, the company reinforced a clear strategic plan, reaffirmed 2026 guidance, and emphasized productivity/AI initiatives and reinvestment into high‑impact R&D, suggesting the positives materially outweigh the near‑term negatives.View all DE:PFE earnings summariesPFE Revenue Breakdown
47.36% Primary Care
26.17% Specialty Care
24.54% Oncology
1.80% PFIZER CENTREONE
0.13% PFIZER IGNITE
PFE Stock 12 Month Forecast
Average Price Target
€24.45
▲(7.41% Upside)
Technical Analysis
Options Prices
Currently, No data available
---